Research Article
Open-Label Placebo Trial among Japanese Patients with Chronic Low Back Pain
Table 1
Comparision of parameters at the baseline TAU group and TAU + OLP group
| | | TAU (n = 26) | OLP + TAU (n = 26) | Comparison ( value) |
| | Female, n (%) | 15 (57.7) | 17 (65.4) | 0.78 | | Age (years) | 65.3 (13.8) | 68.2 (13.0) | 0.38 | | BMI (kg.m2) | 22.4 (4.0) | 24.1 (6.4) | 0.55 | | RMDQ (range: 0–24) | 10.3 (4.0) | 9.9 (3.7) | 0.72 | | NRS (range: 3–10) | 5.5 (1.6) | 5.3 (1.9) | 0.48 | | TUG (sec) | 9.1 (2.1) | 8.5 (2.0) | 0.27 | | History of lumber surgery, n (%) | 7 (26.9%) | 11 (42.3%) | 0.38 | | Pain duration | | | 0.41 | | 6 months–1 year | 8 (30.8%) | 4 (15.4%) | | | 1–5 years | 12 (46.2%) | 14 (53.8%) | | | >5 years | 6 (23.1%) | 8 (30.8%) | | | Use of analgesic drugs, n (%) | 17 (65.4%) | 16 (61.5%) | 1.0 | | NSAID oral | 9 (34.6%) | 5 (19.2%) | | | NSAID transdermal | 5 (19.2%) | 4 (15.4%) | | | Acetaminophen | 3 (11.5%) | 2 (7.7%) | | | Pregabalin | 5 (19.2%) | 4 (15.4%) | | | Duloxetine | 0 | 0 | | | Weak opioid | 2 (7.7%) | 2 (7.7%) | | | Strong opioid | 0 | 0 | | | An extract | 0 | 1 (3.8%) | | | Others | 4 (15.4%) | 2 (7.7%) | |
|
|
An extract: an extract from inflamed cutaneous tissue of rabbits inoculated with vaccinia virus. |
